Enhanced tumor delivery and antitumor activity of palmitoyl rhizoxin using stable lipid emulsions in mice

Pharmaceutical Research

Volumn 13, Issue 2, 1996, Pages 305-310

  Kurihara, Atsushi ^a   Shibayama, Yoko ^a   Mizota, Atsuko ^a   Yasuno, Akiko ^a   Ikeda, Masaru ^a   Sasagawa, Kazuhiko ^a   Kobayashi, Tomowo ^a   Hisaoka, Masafumi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Antitumor activity; Emulsions; Pharmacokinetics; RS 1541(palmitoyl rhizoxin); Toxicity

Indexed keywords

LIPID EMULSION; RHIZOXIN; RICINOMACROGOL; RS 1541; SURFACTANT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SARCOMA; SURVIVAL TIME; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CASTOR OIL; CHEMISTRY, PHARMACEUTICAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; EMULSIONS; FEMALE; LACTONES; LYMPHOMA, LARGE-CELL; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; SURFACE-ACTIVE AGENTS; TRIGLYCERIDES;

EID: 0029914973     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016063719541     Document Type: Article

References (12)

1. M. Takahashi, S. Iwasaki, H. Kobayashi, S. Okuda, T. Murai, and Y. Sato. Rhizoxin binding to tubulin at the maytansine-binding site. Biochm. Biophys. Acta 926:215-223 (1987).
2. T. Kobayashi, K. Sasagawa, K. Hirai, T. Nishimura, T. Tsuruo, S. Iwasaki, S. Tsukagoshi, and S. Okuda. Antitumor activities of new antitumor antibiotic derivatives, acylated rhizoxins. In Abstracts of the 16th International Congress of Chemotherapy, Jerusalem, Israel, 1989, pp. 739. 1-2.
3. D. D. Lasic, F. J. Martin, A. Gabizon, S. K. Huang, and D. Papahadjopoulos. Sterically stabilized liposome: a hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta 1070:187-192 (1991).
4. A. Kurihara, Y. Shibayama, A. Mizota, A. Yasuno, M. Ikeda, K. Sasagawa, T. Kobayashi, and M. Hisaoka. Lipid emulsions of palmitoyl rhizoxin: effects of composition on lipolysis and biodistribution. Biopharm. Drug Disposit. (in press)
5. A. Kurihara, Y. Shibayama, A. Yasuno, M. Ikeda, and M. Hisaoka. Lipid emulsions of palmitoyl rhizoxin: Effects of particle size on blood dispositions of emulsion lipid and incorporated compound in rats. Biopharm. Drug Disposit. (in press)
6. A. Kurihara, Y. Shibayama, A. Mizota, A. Yasuno, M. Ikeda, and M. Hisaoka. Pharmacokinetics of highly lipophilic antitumor agent palmitoyl rhizoxin incorporated in lipid emulsions in rats. Biol.Pharm.Bull. (in press)
7. K. Y. Robert, Z. Cheng, and C. C. Cheng. Delivery of anticancer drugs. Meth. and Find. Exp. Clin. Pharmacol. 11:439-529 (1989).
8. R. Perez-Soler, and W. Priebe, W. Liposomal formulation and antitumor activity of 14-O-palmitoyl-hydroxyrubicin. Cancer Chemother. Pharmacol. 30:267-271 (1992).
9. P. Couvreur, L. Roblot-Treupel, M. F. Poupon, F. Brasseur, and F. Puisieux. Nanoparticles as microcarriers for anticancer drugs. Adv. Drug Del. Rev. 5:209-230 (1990).
10. L. C. Collins-Gold, R. T. Lyons, and L. C. Bartholow. Parenteral emulsions for drug delivery. Adv. Drug Del. Rev. 5:189-208 (1990).
11. T. Tanaka, Y. Kaneo, S. Shiramoto, and S. Iguchi. The dispositions of serum proteins as drug-carriers in mice bearing sarcoma 180. Biol. Pharm. Bull. 16:1270-1275 (1993).
12. A. Gabizon and D. Papahadjopoulos. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA 85:6949-6953 (1988).